Servier Renews and Expands License to Aureus
News Mar 02, 2006
Aureus Pharma has announced that Servier has both renewed their previous license to Aureus’ AurSCOPE ADME/Drug-Drug Interactions (ADME/DDI) knowledge database and expanded the license to include AurSCOPE GPCR as well.
Servier became Aureus’ first customer of the AurSCOPE ADME/DDI knowledgebase in 2002. During the subsequent years, Aureus and Servier have collaborated closely to develop and enhance the AurSCOPE ADME/DDI.
This knowledge database contains all relevant biological and chemical information related to the metabolic properties of drugs and is designed to assist in the identification of potential drug-drug interactions.
"We have found that Aureus Pharma’s high quality ADME/ Drug-Drug Interaction knowledge databases are a source of crucial information in identifying potential adverse drug-drug interactions," said Dr. Bernard Marchand, Servier’s Director of Biopharmacy.
"We also look forward to applying the AurSCOPE GPCR knowledgebase in a variety of our disease targeted programs," added Dr. Emmanuel Canet, Vice President Research at Servier.
"We are delighted that Servier has chosen to continue their collaboration with Aureus Pharma," said Dr. Andre Michel, CEO of Aureus Pharma.
"Strong partnership with pharmaceutical companies such as Servier is strategic to Aureus in the ongoing development of solutions fitting with the needs of our end users."
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE